http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 10:44:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Mar+02/26089046.html si-local-file:///var/storage/secattach/20260302/26089046.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Mar+02/26089046.html Mon, 02 Mar 2026 10:44:00 -0500 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Mar+02/26089046.html si-local-file:///var/storage/secattach/20260302/26089046.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Mar+02/26089046.html Mon, 02 Mar 2026 10:44:00 -0500 O.02608059 ONCY http://www.streetinsider.com/Corporate+News/Oncolytics+Biotech+starts+phase+2+colorectal+cancer+study/26088102.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the initiation of a Phase 2 study for metastatic colorectal cancer, designated as REO 033. The randomized controlled trial will evaluate the company's investigational drug pelareorep in combination with standard treatments.</p><p>The study will enroll 60 patients with second-line RAS-mutated, microsatellite-stable metastatic colorectal cancer who have failed initial platinum-based chemotherapy. Participants will be randomized into two 30-patient arms: a control group receiving bevacizumab and FOLFIRI, and an experimental group receiving pelareorep, bevacizumab, and FOLFIRI.</p><p>The primary endpoint is objective response rate, with progression-free survival, overall survival, safety, and biomarker analysis as secondary endpoints. Oncolytics expects to http://www.streetinsider.com/Corporate+News/Oncolytics+Biotech+starts+phase+2+colorectal+cancer+study/26088102.html Mon, 02 Mar 2026 09:02:00 -0500 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html <p align="center"><em>Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026</em></p> <p align="center"><em>Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication</em></p> <p align="justify">SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the initiation of a metastatic colorectal cancer (“mCRC”) Phase 2 study that will be referred to as REO 033.</p> <p align="justify">In this trial, second-line (“2L”) RAS-mutated (which includes http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Launches+Randomized+Colorectal+Cancer+Study/26087961.html Mon, 02 Mar 2026 09:00:00 -0500 A.06822034 A.33615634 A.50213784 O.02608059 O.07116439 O.08407916 O.20026344 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Feb+24/26048088.html si-local-file:///var/storage/secattach/20260224/26048088.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Feb+24/26048088.html Tue, 24 Feb 2026 09:11:00 -0500 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Feb+24/26048088.html si-local-file:///var/storage/secattach/20260224/26048088.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Feb+24/26048088.html Tue, 24 Feb 2026 09:11:00 -0500 O.02608059 ONCY http://www.streetinsider.com/Corporate+News/Oncolytics+shifts+focus+to+anal%2C+colorectal+cancer+studies/26047917.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced it will wind down enrollment in its GOBLET gastrointestinal study to concentrate resources on registration-focused programs in squamous cell anal cancer and metastatic colorectal cancer.</p><p>The clinical-stage immunotherapy company concluded enrollment in the GOBLET study after generating clinical and translational data to inform its development strategy. The company stated it has sufficient cash to execute near-term milestones without immediate material dilution.</p><p>Oncolytics plans to pursue regulatory approval for its pelareorep therapy in second-line and later squamous cell anal cancer based on efficacy signals observed in GOBLET Cohort 4. The company expects to meet with the U.S. http://www.streetinsider.com/Corporate+News/Oncolytics+shifts+focus+to+anal%2C+colorectal+cancer+studies/26047917.html Tue, 24 Feb 2026 09:01:55 -0500 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+to+Prioritize+Registration-Focused+Programs+in+Anal+and+Colorectal+Cancer/26047741.html <p align="center"><em>Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S.</em></p> <p align="center"><em>With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution</em></p> <p align="justify">SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has concluded enrollment in the GOBLET study, having generated the necessary clinical and translational data to inform its next phase of development. With sufficient cash on hand to execute near-term milestones, the Company http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+to+Prioritize+Registration-Focused+Programs+in+Anal+and+Colorectal+Cancer/26047741.html Tue, 24 Feb 2026 09:00:00 -0500 A.06822034 A.50213784 O.02608059 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+to+Prioritize+Registration-Focused+Programs+in+Anal+and+Colorectal+Cancer/26047741.html <p align="center"><em>Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S.</em></p> <p align="center"><em>With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution</em></p> <p align="justify">SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has concluded enrollment in the GOBLET study, having generated the necessary clinical and translational data to inform its next phase of development. With sufficient cash on hand to execute near-term milestones, the Company http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+to+Prioritize+Registration-Focused+Programs+in+Anal+and+Colorectal+Cancer/26047741.html Tue, 24 Feb 2026 09:00:00 -0500 A.06822034 A.50213784 O.02608059 O.08407916 O.20026344 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+to+Prioritize+Registration-Focused+Programs+in+Anal+and+Colorectal+Cancer/26047741.html <p align="center"><em>Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S.</em></p> <p align="center"><em>With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution</em></p> <p align="justify">SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has concluded enrollment in the GOBLET study, having generated the necessary clinical and translational data to inform its next phase of development. With sufficient cash on hand to execute near-term milestones, the Company http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+to+Prioritize+Registration-Focused+Programs+in+Anal+and+Colorectal+Cancer/26047741.html Tue, 24 Feb 2026 09:00:00 -0500 A.06822034 A.50213784 O.02608059 O.08407916 O.20026344 ONCY